Impact of out-of-pocket expenses on discontinuation of statin therapy: A cohort study in Finland

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 58-64

  Helin Salmivaara, A ^a,b   Korhonen, M J ^a,c   Alanen, T ^a   Huupponen, R ^a,d  

^a UNIVERSITY OF TURKU   (Finland)

^b HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

expenses; persistence; statin

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG COST; DRUG WITHDRAWAL; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; REGISTER; SYSTEMATIC ERROR;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG COSTS; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; FINLAND; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRROLES; REGISTRIES; SIMVASTATIN;

EID: 84856338141     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01250.x     Document Type: Article

References (31)

1. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation, 2007; 14: S1-S113. (Pubitemid 47339826)
2. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S, Impact of adherence to statins on coronary artery disease in primary prevention. British Journal of Clinical Pharmacology, 2007; 63: 698-708. (Pubitemid 46753568)
3. Perreault S, Dragomir A, Blais L, Berard A, Lalonde L, White M, Pilon D, Impact of better adherence to statin agents in the primary prevention of coronary artery disease. European Journal of Clinical Pharmacology, 2009; 65: 1013-1024.
4. Sabaté E, (ed.) Adherence to long-term therapies: evidence for action. Geneva: WHO.
5. Osterberg L, Blaschke T, Adherence to medication. New England Journal of Medicine, 2005; 353: 487-497. (Pubitemid 41127293)
6. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Archives of Internal Medicine, 2006; 166: 332-337. (Pubitemid 43244321)
7. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM, Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Journal of General Internal Medicine, 2004; 19: 638-645.
8. Goldman DP, Joyce GF, Karaca-Mandic P, Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. The American Journal of Managed Care, 2006; 12: 21-28. (Pubitemid 43139537)
9. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S, The effects of prescription drug copayments on statin adherence. The American Journal of Managed Care, 2006; 12: 509-517. (Pubitemid 44412033)
10. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ, Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation, 2007; 115: 2128-2135. (Pubitemid 46659064)
11. Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Medical Care, 2010; 48: 196-202.
12. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG, The effect of incentive-based formularies on prescription-drug utilization and spending. New England Journal of Medicine, 2003; 349: 2224-2232. (Pubitemid 37485139)
13. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG, Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation, 2009; 119: 390-397.
14. Sedjo RL, Cox ER, Lowering copayments: impact of simvastatin patent expiration on patient adherence. The American Journal of Managed Care, 2008; 14: 813-818.
15. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT, The Nordic countries as a cohort for pharmacoepidemiological research. Basic and Clinical Pharmacology and Toxicology, 2010; 106: 86-94.
16. WHO. About the ATC/DDD system. Available at: (accessed 4 April 2009).
17. National Agency for Medicines and Social Insurance Institution Finnish statistics on medicines 2003. Helsinki: National Agency for Medicines and Social Insurance Institution.
18. National Agency for Medicines and Social Insurance Institution Finnish statistics on medicines 2005. Helsinki: National Agency for Medicines and Social Insurance Institution.
19. Helin-Salmivaara A, Lavikainen P, Korhonen MJ, et al. Long-term persistence with statin therapy: a nation-wide register study. Clinical Therapeutics, 2008; 30: 2228-2240.
20. National Agency for Medicines and Social Insurance Institution (2005) Finnish statistics on medicines 2004. Helsinki: National Agency for Medicines and Social Insurance Institution.
21. Law MR, Wald NJ, Rudnicka AR, Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003; 326: 1423-1430.
22. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J, Long-term persistence in use of statin therapy in elderly patients. JAMA, 2002; 288: 455-461. (Pubitemid 34787476)
23. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J, Persistence of use of lipid-lowering medications: a cross-national study. JAMA, 1998; 279: 1458-1462. (Pubitemid 28228203)
24. Thiebaud P, Patel BV, Nichol MB, Berenbeim DM, The effect of switching on compliance and persistence: the case of statin treatment. The American Journal of Managed Care, 2005; 11: 670-674. (Pubitemid 41608208)
25. Steiner JF, Can we identify clinical predictors of medication adherence... and should we? Medical Care, 2010; 48: 193-195.
26. Dortmuth C, Schneewiss S, Brookhart A, Basset K, Wright JM, Factors related to splitting tablets of HGM-CoA reductace inhibitors: a population-based analysis in British Columbia. Pharmacoepidemiology and Drug Safety, 2007; 16: S137.
27. Gumbs PD, Verschuren WM, Souverein PC, Mantel-Teeuwisse AK, de Wit GA, de Boer A, Klungel OH, Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. British Journal of Clinical Pharmacology, 2007; 64: 680-685. (Pubitemid 47568822)
28. Donohue JM, Fischer MA, Huskamp HA, Weissman JS, Potential savings from an evidence-based consumer-oriented public education campaign on prescription drugs. Health Services Research, 2008; 43: 1557-1575.
29. Atar D, Carmena R, Clemmensen P, A KL, Wassmann S, Lansberg P, Hobbs R, Clinical review: impact of statin substitution policies on patient outcomes. Annals of Medicine, 2009; 41: 242-256.
30. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH, Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA, 2008; 300: 2514-2526.
31. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA, 2001; 285: 421-429. (Pubitemid 32097260)